NFKB1 and primary cutaneous T-cell non-Hodgkin lymphoma: CTCL, including its leukemic variant Sézary syndrome, is characterized by a CD4+, CD45RO+ and CD8− phenotype and an elevated expression of constitutively active NFκB accompanied by resistance to PCD2, 20, 33.